Kanvas Biosciences has secured $48 million in Series B funding to develop treatments that use the microbiome to fight cancer. The company aims to harness the human gut microbiome to create therapies that can improve responses to existing cancer treatments, such as immune checkpoint inhibitors. According to a report from the Cornell Chronicle, the funding round was led by new and existing investors, and the money will be used to advance the company’s lead drug candidate into human clinical trials and to expand its platform for discovering bacteria-based therapies.

Key takeaways

  • Kanvas Biosciences raised $48 million to support microbiome-based cancer therapy development.
  • The company’s lead candidate targets the gut microbiome to boost the effectiveness of immunotherapy.
  • The funding round was led by investors including those with expertise in biotechnology and oncology.
  • The company plans to start clinical trials in the near future and to scale its drug discovery platform.
  • Microbiome therapies are an emerging area of cancer research, with potential to improve patient outcomes.

What the funding means for Kanvas Biosciences

The $48 million Series B financing will allow Kanvas Biosciences to take its lead therapeutic candidate into phase 1 clinical trials. The company also intends to use the capital to expand its proprietary platform, which identifies specific gut bacteria strains that can influence the immune system. By engineering these bacteria or using them as live biotherapeutics, Kanvas aims to create treatments that make tumors more susceptible to immune attack. The funding round included participation from investors like the Cornell University-affiliated funds and others in the biotech space.

How microbiome therapies work in cancer

The human gut microbiome consists of trillions of bacteria, viruses, and fungi that play a role in digestion, immunity, and overall health. Research over the past decade has shown that the composition of gut bacteria can influence how well a patient responds to cancer treatments, especially immunotherapies known as checkpoint inhibitors. These drugs work by “releasing the brakes” on immune cells so they can attack tumors. However, many patients do not respond to these drugs, and studies have linked poor responses to certain imbalances in gut bacteria. Kanvas Biosciences is developing therapies that aim to correct those imbalances or introduce beneficial bacteria to improve treatment outcomes.

Details from the Cornell Chronicle report

According to the Cornell Chronicle article, Kanvas Biosciences was spun out of Cornell University and has built a platform that combines high-throughput screening with genomics to discover bacteria that modulate immune responses. The company’s technology allows it to test thousands of bacterial strains simultaneously for their ability to enhance or suppress immune cell activity. The lead candidate is designed to be used alongside existing immunotherapies. The funding round brings the total amount raised by Kanvas to over $70 million since its founding, as reported by the Chronicle.

Potential impact on cancer treatment

If Kanvas Biosciences’ approach proves successful in clinical trials, it could offer a new tool for oncologists to help patients who do not respond well to current immunotherapies. Microbiome therapies are generally considered safe because they involve natural gut bacteria, though rigorous testing is still needed. The company’s platform could also be adapted to treat other diseases, such as autoimmune conditions or infections. Industry observers note that microbiome-based cancer therapies are still in early stages, but the funding signals growing investor confidence in this field.

Frequently Asked Questions

What is a microbiome cancer therapy?

A microbiome cancer therapy uses live bacteria or other microbes to alter the gut ecosystem in order to improve the body’s immune response against tumors. These therapies can be given as pills or capsules and are designed to work alongside standard cancer treatments like immunotherapy or chemotherapy.

Is microbiome therapy safe?

Most microbiome therapies under investigation use strains of bacteria that are generally regarded as safe because they naturally occur in the human gut. However, because these are live organisms, clinical trials carefully monitor for any unintended effects. Early studies have shown that such therapies are usually well tolerated, with mild gastrointestinal side effects being the most common.

When will Kanvas Biosciences start clinical trials?

According to the Cornell Chronicle report, the company plans to use the new funding to advance its lead candidate into phase 1 clinical trials. While a specific date was not provided, the funding announcement suggests that trials could begin within the next one to two years, pending regulatory approvals and further preclinical work.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.